Evidence-guided tumour profiling offers new hope for clinicians managing difficult-to-treat cancers
10/01/2013
Data from two studies presented at the 2013 European Cancer Congress (ECC 2013), announced by Caris Life Sciences, demonstrate the potential of evidence-guided tumour profiling to immediately improve the treatment of patients with hard-to-treat cancers, including cancers of unknown primary (CUP) and rarer and refractory cancers...
The importance of telomere length in prostate cancer prognosis
10/01/2013
Like the plastic caps at the end of shoelaces, telomeres protect - in their case - the interior-gene containing parts of chromosomes that carry a cell's instructional material...
Progression of squamous cell carcinomas reduced in mice
10/01/2013
The c-Fos oncogene has traditionally been linked to cellular activities related to cancer, such as cell division, differentiation - conversion from one cell type to another - or survival. Any alteration of these activities can set off the development of tumours, which has made c-Fos an important target for the understanding and treatment of cancer...
Deadly form of lung cancer may be treatable with FDA-approved antidepressant
10/01/2013
A little-used class of antidepressants appears potentially effective in combating a particularly deadly form of lung cancer, according to a new study from researchers at the Stanford University School of Medicine. And because the drugs have already been approved by the U.S...
'Irrefutable' evidence that colorectal cancer screening has led to fall in death rates
10/01/2013
Screening for colorectal cancer (CRC) in European countries is highly effective in reducing mortality from the disease...
Melanoma patients treated with ipilimumab can survive up to 10 years
10/01/2013
Patients with advanced melanoma, who have been treated with the monoclonal antibody, ipilimumab, can survive for up to ten years, according to the largest analysis of overall survival for these patients, presented at the 2013 European Cancer Congress (ECC2013) [1]...
Increased mortality risk for younger patients with metastatic colorectal cancer
10/01/2013
Younger patients with colorectal cancer that has spread (metastasised) to other parts of the body represent a high-risk group that is less likely to respond to anti-cancer treatments. Their disease is more likely to progress and they are at greater risk of death than other age groups, according to new reseach presented to the 2013 European Cancer Congress (ECC2013) [1]...
Study finds new moves in protein's evolution: Findings point to new approach to drug design
10/01/2013
Highlighting an important but unexplored area of evolution, scientists at The Scripps Research Institute (TSRI) have found evidence that, over hundreds of millions of years, an essential protein has evolved chiefly by changing how it moves, rather than by changing its basic molecular structure...
In advanced papillary kidney cancer, everolimus slows disease progression
10/01/2013
The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease, according to research presented at the 2013 European Cancer Congress (ECC2013) [1]...
The search for cancer genes could be aided by new survey of DNA alterations
10/01/2013
Scanning the DNA of nearly 5,000 tumor samples, a team led by scientists at Dana-Farber Cancer Institute and the Broad Institute has identified 140 regions of scrambled genetic code believed to contain many undiscovered cancer genes...